Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease

Movement Disorders

Volumn 18, Issue 2, 2003, Pages 138-149

  Segovia, Gregorio ^a,b   Mora, Francisco ^b   Crossman, Alan R ^a,c   Brotchie, Jonathan M ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Williams House   (United Kingdom)

Author keywords

Cannabinoids; CB1 receptors; Dyskinesia; L dopa; Reserpine

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BENSERAZIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; QUINPIROLE; RESERPINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; DYSKINESIA; HYPERKINESIA; LONG TERM CARE; MALE; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; FATTY ACIDS, UNSATURATED; HYPERKINESIS; LEVODOPA; MALE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RESERPINE; TIME FACTORS;

EID: 0344406282     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10312     Document Type: Review

References (49)

1. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-583.
2. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992;48:655-668.
3. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000;14:1432-1438.
4. Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. Eur J Neurosci 1997;9: 199-203.
5. Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999;65:703-713.
6. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991;547:267-274.
7. 1. J Comp Neurol 2000;422:159-171.
8. Smith AD, Bolam JP. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 1990;13:259-265.
9. Kita H. GABAergic circuits of the striatum. In: Arbuthnott GW, Emson PC, editors. Progress in brain research. Amsterdam: Elsevier Science Research; 1993. p 51-72.
10. Pertwee RG, Wickens AP. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991;30:237-244.
11. 9-tetrahydrocannabinol on circling in rats induced by intranigral muscimol administration. Eur J Pharmacol 1995;282:251-254.
12. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996;308:161-164.
13. Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996;22:382-385.
14. Romero J, de Miguel R, Ramos JA, Fernández-Ruiz JJ. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci 1998;62:351-363.
15. Tersigni TJ, Rosenberg HC. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 1996;733:184-192.
16. Chan PKY, Yung W-H. Occlusion of the presynaptic action of cannbinoids in rat substantia nigra pars reticulata by cadmium. Neurosci Lett 1998;249:57-60.
17. Miller AS, Walker JM. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur J Pharmacol 1996;304:29-35.
18. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 2000;97:89-97.
19. Sañudo-Peña MC, Walker JM. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 1997;77:1635-1638.
20. Szabo B, Dörner L, Pfreundtner C, Nörenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 1998;85:395-403.
21. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001;85:468-471.
22. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia in Parkinson's disease: opportunities for novel treatments. Nat Rev Neurosci 2001;2:577-588.
23. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
24. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
25. Crossman AR. Functional anatomy of movement disorders. J Anat 2000;196:519-525.
26. Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann Neurol 2000;47: S105-S114.
27. Lastres-Becker I, Cebeira M, De Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernandez-Ruiz JJ. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 2001;14:1827-1832.
28. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999;2:358-363.
29. 1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 1997;148:265-270.
30. Zeng B-Y, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P. Chronic L-dopa treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett 1999;276:71-74.
31. Silverdale MA, McGuire SG, McInnes A, Crossman AR, Brotchie JM. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 2001;169:400-406.
32. Mailleux P, Vanderhaeghen J-J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 1993;61:1705-1712.
33. Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernandez-Ruiz JJ, de Yebenes JG, Ramos JA. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 2000;66:485-494.
34. Fox SH, Hill MP, Crossman AR, Brotchie JM. On the role of endocannabinoids in L-dopa-induced dyskinesia. Soc Neurosci Abstr 1999;25:1462.
35. Sieradzan KA, Fox SH, Dick J, Brotchie JM. The effects of the cannabinoid receptor agonist, nabilone on L-dopa-induced dyskinesia in patients with idiopathic Parkinson's disease. Mov Disord 1998;13(Suppl. 2):29.
36. Colpaert FC. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 1987;26:1431-1440.
37. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990;28:539-546.
38. Koller W, Herbster G, Anderson D, Wack R, Gordon J. Quinpirole hydrochloride, a potential anti-parkinsonism drug. Neuropharmacology 1987;26:1031-1036.
39. Ossowska K. The role of excitatory amino acids in experimental models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994;8:39-71.
40. Nash JE, Hill MP, Brotchie JM. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp Neurol 1999;155:42-48.
41. Dawson L, Chadha A, Megalou M, Duty S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 2000;129:541-546.
42. Savola J-M, Hill MP, Merivuori H, McGuire SG, Crossman AR, Brotchie JM. JP-1730, a novel α2-adrenergic antagonist, reduces L-dopa-induced dyskinesia in animal models of Parkinson's disease. Soc Neurosci Abstr 2001;27:200.6.
43. Hill MP, McGuire SG, Crossman AR, Brotchie JM. The mGlu5 receptor antagonist SIB-1830 reduces L-dopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Soc Neurosci Abstr 2001;27:200.17.
44. Ameri A. The effects of cannabinoids in the brain. Prog Neurobiol 1999;58:315-348.
45. Souilhac J, Pocellet M, Rinaldi-Carmona M, Le Fur G, Soubrié P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 1995;51:3-7.
46. 2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res 1995;691:106-114.
47. 2 receptor responses by an anandamide transport inhibitor. J Neurosci 2000;20:3401-3407.
48. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998;38:179-200.
49. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;21:521-528.